According to novel coronavirus pneumonia (EMA), Guido Laci, GuidoRasi, said in a hearing on the European Parliament that the agency would approve the Remdesivir, an antiviral drug developed by Gilead, in May 18th, to treat new crown pneumonia, according to Reuters reported on May 18th. Radcivir is likely to get a conditional listing permit in the near future, rassie said
The novel coronavirus pneumonia has been recommended by the European Medicines Agency for the Reed crown to be treated with no more than drugs.
In addition to radcivir, monoclonal antibody based therapies may also be used in the near future, RASI said. It is reported that the treatment can neutralize the new coronavirus.
Gilead R & D ridcivir was originally planned to be used for diseases such as Ebola haemorrhagic fever and Middle East respiratory syndrome. Novel coronavirus pneumonia was approved by the US Food and Drug Administration (FDA) in March 23rd. Reed approved the orphan drug certification in March 23rd. In May 1st, the emergency use authorization was granted to allow the emergency use of new acute pneumonia. Novel coronavirus pneumonia was also approved by Reed in May 7th. Many countries also conducted novel coronavirus pneumonia trials with Reeds way.
Extend reading for survival! Huaweis strong response to the U.S. blockade: theres no way to go but to win. Yu Chengdong: the U.S. crackdown on Huawei is to maintain the hegemony of science and technology. Huawei urgently sends a $700 million bill to TSMC, which denies receiving new orders. Source: surging news editor: Qiao JunJing u00b7 nbj11279